tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Aug 31;228(Supplement_2):S126-S135.
doi: 10.1093/infdis/jiad286. Long COVID After Bamlanivimab Treatment
Teresa H Evering[SUP] 1 [/SUP], Carlee B Moser[SUP] 2 [/SUP], Nikolaus Jilg[SUP] 3 [/SUP], Eunice Yeh[SUP] 2 [/SUP], Busola Sanusi[SUP] 2 [/SUP], David A Wohl[SUP] 4 [/SUP], Eric S Daar[SUP] 5 [/SUP], Jonathan Z Li[SUP] 3 [/SUP], Paul Klekotka[SUP] 6 [/SUP], Arzhang Cyrus Javan[SUP] 7 [/SUP], Joseph J Eron[SUP] 4 [/SUP], Judith S Currier[SUP] 8 [/SUP], Michael D Hughes[SUP] 2 9 [/SUP], Davey M Smith[SUP] 10 [/SUP], Kara W Chew[SUP] 8 [/SUP]; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
Background: Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.
Methods: Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.
Results: Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.
Conclusions: Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.
Clinical trials registration: NCT04518410.
Keywords: bamlanivimab; clinical trial; long COVID; postacute sequelae of SARS-CoV-2 infection (PASC); symptom.
. 2023 Aug 31;228(Supplement_2):S126-S135.
doi: 10.1093/infdis/jiad286. Long COVID After Bamlanivimab Treatment
Teresa H Evering[SUP] 1 [/SUP], Carlee B Moser[SUP] 2 [/SUP], Nikolaus Jilg[SUP] 3 [/SUP], Eunice Yeh[SUP] 2 [/SUP], Busola Sanusi[SUP] 2 [/SUP], David A Wohl[SUP] 4 [/SUP], Eric S Daar[SUP] 5 [/SUP], Jonathan Z Li[SUP] 3 [/SUP], Paul Klekotka[SUP] 6 [/SUP], Arzhang Cyrus Javan[SUP] 7 [/SUP], Joseph J Eron[SUP] 4 [/SUP], Judith S Currier[SUP] 8 [/SUP], Michael D Hughes[SUP] 2 9 [/SUP], Davey M Smith[SUP] 10 [/SUP], Kara W Chew[SUP] 8 [/SUP]; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
- PMID: 37650236
- DOI: 10.1093/infdis/jiad286
Background: Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.
Methods: Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.
Results: Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.
Conclusions: Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.
Clinical trials registration: NCT04518410.
Keywords: bamlanivimab; clinical trial; long COVID; postacute sequelae of SARS-CoV-2 infection (PASC); symptom.